Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU2-59P is a pseudogene member of the U2 small nuclear RNA gene family. U2 snRNA is an essential component of the major spliceosome, which is responsible for pre-mRNA splicing in eukaryotes. However, RNU2-59P does not encode a functional snRNA—it is a noncoding remnant with no known biological activity or disease association[1]. It is annotated as part of the snRNA gene family due to sequence similarity but does not produce a functional transcript or protein. This pseudogene is not associated with receptor, enzyme, transporter, or other canonical drug targets, nor is it used for therapeutic purposes. There is no evidence that it acts as a biomarker or interacts with drugs, and it does not present safety concerns in biomedical contexts[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 59, pseudogene (RNU2-59P).